肌注利培酮微球与口服利培酮治疗精神分裂症疗效研究
梁松新;王秋琴;麦以成;邓良华
【期刊名称】《中国医疗前沿》 【年(卷),期】2013(000)005
【摘要】 目的探讨肌注利培酮微球与口服利培酮治疗精神分裂症的疗效,为临床选择药物提供依据.方法将80例精神分裂症患者随机分成肌注利培酮微球(RLAI)组及口服利培酮片组,治疗12周.在治疗第1、4、8、12周用阳性与阴性症状量表(PANSS)、临床疗效总评量表(CGI-SI)、不良反应量表(TESS)评定疗效和不良反应.结果两组PANSS总分及CGI-SI评分均比治疗前显著下降(P<0.01),与基线比较,PANSS评分自4周末以后均出现显著差异,两组疗效相当.RLAI组的不良反应明显低于口服利培酮片组(P<0.05).结论肌注利培酮微球与口服利培酮片治疗精神分裂症的疗效相当,RLAI组的不良反应较口服利培酮少而轻.肌注利培酮微球治疗精神分裂症安全有效,患者对治疗依从性比口服利培酮更好.%Objective To investigate the efficacy of intramuscular risperidone microspheres and oral risperidone in the treatment of schizophrenia, and to provide the basis for clinical drug of choice. Methods 80 cases of patients with schizophrenia were randomly divided into intramuscular risperidone microspheres(RLAI) group and the oral risperidone piece group, 12 weeks of treatment. Evaluate the efficacy and adverse reactions in the treatment of 1, 4, 8 and 12 weeks using the Positive and Negative Syndrome Scale(PANSS), the Clinical Global Impression(CGI-SI), adverse reactions Scale(TESS). Results The PANSS total score and CGI-SI
肌注利培酮微球与口服利培酮治疗精神分裂症疗效研究
